The BtaF Adhesin Is Necessary for Full Virulence During Respiratory Infection by Brucella suis and Is a Novel Immunogen for Nasal Vaccination Against Brucella Infection

Autor: Florencia Muñoz González, Gabriela Sycz, Iván M. Alonso Paiva, Dirk Linke, Angeles Zorreguieta, Pablo C. Baldi, Mariana C. Ferrero
Jazyk: angličtina
Rok vydání: 2019
Předmět:
0301 basic medicine
CD4-Positive T-Lymphocytes
Immunogen
Brucella suis
Ciencias de la Salud
Adaptive Immunity
BACTERIAL ADHESINS
Mice
0302 clinical medicine
BTAF AUTOTRANSPORTER
respiratory infection
Immunology and Allergy
intragastric challenge
Original Research
biology
Virulence
Respiratory infection
medicine.anatomical_structure
Female
purl.org/becyt/ford/3 [https]
Antibody
Dinucleoside Phosphates
lcsh:Immunologic diseases. Allergy
CIENCIAS MÉDICAS Y DE LA SALUD
Immunology
bacterial adhesins
BRUCELLA SUIS
Spleen
INTRAGASTRIC CHALLENGE
Brucellosis
Microbiology
03 medical and health sciences
purl.org/becyt/ford/3.3 [https]
Immune system
medicine
nasal immunization
Animals
Humans
Adhesins
Bacterial

Immunity
Mucosal

Administration
Intranasal

BtaF autotransporter
Antigens
Bacterial

Bacterial adhesin
Enfermedades Infecciosas
030104 developmental biology
Immunization
MUCOSAL IMMUNITY
biology.protein
mucosal immunity
RESPIRATORY INFECTION
lcsh:RC581-607
NASAL IMMUNIZATION
030215 immunology
Zdroj: CONICET Digital (CONICET)
Consejo Nacional de Investigaciones Científicas y Técnicas
instacron:CONICET
Frontiers in Immunology
Frontiers in Immunology, Vol 10 (2019)
ISSN: 1664-3224
DOI: 10.3389/fimmu.2019.01775/full
Popis: Brucella enters their hosts mostly through mucosae from where it spreads systemically.Adhesion to extracellular matrix (ECM) components or to host cells is important for theinfectious process, and is mediated by several adhesins, including the BtaF trimericautotransporter. Although Th1 responses and gamma interferon (IFN-g) are important forprotection, antibodies able to block adhesions might also contribute to prevent Brucellainfection. We evaluated the importance of BtaF for respiratory Brucella infection, andcharacterized the immune response and protection from mucosal challenge induced bynasal vaccination with recombinant BtaF. While lung CFU numbers did not differ at day1 p.i. between mice intratracheally inoculated with B. suis M1330 (wild type) and thosereceiving a 1btaF mutant, they were reduced in the latter group at 7 and 30 days p.i.For vaccination studies the BtaF passenger domain was engineered and expressed asa soluble trimeric protein. Mice were immunized by the nasal route with BtaF or saline(control group) plus the mucosal adjuvant c-di-AMP. Specific anti-BtaF antibodies (IgGand IgA) were increased in serum, including a mixed IgG2a/IgG1 response. In vitro,these antibodies reduced bacterial adhesion to A549 alveolar epithelial cells. Specific IgAantibodies were also increased in several mucosae. Spleen cells from BtaF immunizedmice significantly increased their IL-2, IL-5, IL-17, and IFN-g secretion upon antigenstimulation. In cervical draining lymph nodes, antigen-experienced CD4+ T cells weremaintained mainly as central memory cells. A BtaF-specific delayed-type hypersensitivityresponse was detected in BtaF immunized mice. Lung cells from the latter producedhigh levels of IFN-g upon antigen stimulation. Although nasal immunization with BtaF didnot protect mice against B. suis respiratory challenge, it conferred significant protectionfrom intragastric challenge; the splenic load of B. suis was reduced by 3.28 log CFU inimmunized mice. This study shows that nasal vaccination with BtaF+c-di-AMP protectsagainst intragastric challenge with B. suis by inducing local and systemic antibodyresponses, central memory CD4+ T cells and strong Th1 responses. Therefore, althoughBtaF vaccination did not protect fromB. suis respiratory infection, this adhesin constitutesa promising immunogen against mucosal B. suis infection. Fil: Muñoz González, Florencia. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni; Argentina Fil: Sycz, Gabriela. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones Bioquímicas de Buenos Aires. Fundación Instituto Leloir. Instituto de Investigaciones Bioquímicas de Buenos Aires; Argentina Fil: Alonso Paiva, Iván Mathias. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni; Argentina Fil: Linke, Dirk. Centro de Síntesis Ecológica y Evolutiva, Universidad de Oslo; Noruega Fil: Zorreguieta, Ángeles. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones Bioquímicas de Buenos Aires. Fundación Instituto Leloir. Instituto de Investigaciones Bioquímicas de Buenos Aires; Argentina Fil: Baldi, Pablo Cesar. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni; Argentina Fil: Ferrero, Mariana Cristina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni; Argentina
Databáze: OpenAIRE